On December 4, global healthcare leader Vantive formally signed a cooperation agreement with Guangzhou Development District and Huangpu District to establish an automated peritoneal dialysis equipment manufacturing base. The signing marks a new phase of large-scale and high-end development in Guangzhou, underscoring the company’s strategy of operating “in China, for China” and even “in China, for the world.” It also injects strong momentum into the high-quality growth of the biopharmaceutical industry in the Guangdong–Hong Kong–Macao Greater Bay Area.
This agreement represents Vantive’s second investment expansion this year. In June 2025, the company invested in constructing a new production workshop in Guangzhou Development District and Huangpu District, launching localized production of Continuous Renal Replacement Therapy (CRRT) replacement fluids, which will contribute positively to regional economic development and industrial ecosystem building.
In recent years, Guangzhou Development District and Huangpu District have prioritized high-quality foreign investment, closely tracking investment trends among top global enterprises such as Fortune Global 500 companies, major multinational corporations, and industry “single-champion” enterprises. The districts have strengthened support for the establishment of regional headquarters and foreign-invested R&D centers, while promoting business collaboration between industrial-chain anchor enterprises and their upstream and downstream foreign-invested partners to encourage sustained investment and accelerate localization among multinationals.
Today, Guangzhou Development District and Huangpu District have become one of South China’s most concentrated hubs for foreign-invested enterprises. From January to October this year, the districts registered 341 new foreign-invested enterprises, a year-on-year increase of 42%, and utilized USD 1.18 billion in actual foreign investment—ranking first in Guangzhou.